On September 3, 2024 Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, reported that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET (Press release, Bio-Path Holdings, SEP 3, 2024, View Source [SID1234646283]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An audio webcast of the presentation will be available here and on the Investor Relations section of Bio-Path’s website, where it will be archived for approximately 90 days.

On September 3, 2024 BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, reported that it will have an oral presentation on the final efficacy data of Plinabulin and docetaxel combination vs. docetaxel from Dublin-3 phase 3 study in EGFR wild-type 2L/3L non-small cell lung cancer (NSCLC) at the 2024 World Conference on Lung Cancer, on September 9, 2024 in San Diego, CA, and two poster presentations on Dublin-3 study safety outcome and 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) in 2L/3L NSCLC who failed PD-1/PD-L1 inhibitors at European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024, on September 14, 2024 in Barcelona, Spain (Press release, BeyondSpring Pharmaceuticals, SEP 3, 2024, View Source;utm_medium=rss&utm_campaign=beyondspring-announces-oral-presentation-at-the-2024-world-conference-on-lung-cancer-and-two-poster-presentations-during-esmo-congress-2024-showcasing-its-lead-anti-cancer-asset-plinabulin [SID1234646282]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

​​Presentation details are as follows:

2024 World Conference on Lung Cancer

Oral (OA08.04): Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial

Presenter: Trevor M. Feinstein, Principal investigator for Dublin-3 study, Piedmont Cancer Institute, Atlanta, GA, USA
Presentation Time: Monday, September 9, 2024, at 10:57AM to 11:07AM PDT
Session: OA08. The New Generation of Cytotoxics
ESMO Congress 2024

Poster (1358P): Plinabulin/Docetaxel Versus Docetaxel in Survival Benefits of 2L/3L EGFR Wild-Type NSCLC after Platinum Regimens (DUBLIN-3): a Randomized Phase 3 Trial

Presenter: Trevor M. Feinstein
Presentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CEST
Location: Hall 3, Av. Joan Carles I, 64
08908 L’hospitalet de Llobregat

Barcelona, Spain

Session: NSCLC, metastatic
Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization

Presenter: Yan Xu, Investigator, Peking Union Medical College Hospital, Beijing, China
Presentation Time: Saturday, September 14, 2024, at 9AM to 6:30PM CEST
Location: Hall 3, Av. Joan Carles I, 64
08908 L’hospitalet de Llobregat

Barcelona, Spain

Session: NSCLC, metastatic

On September 3, 2024 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported that it has entered into definitive agreements for the issuance and sale of 758,900 shares of its common stock at a purchase price of $8.25 per share and the issuance and sale of pre-funded warrants to purchase up to 3,604,780 shares of its common stock at a purchase price of $8.2499 per share in a registered direct offering, representing a premium of 15% to Atara’s 7-day volume-weighted average price, to entities affiliated with Redmile Group, EcoR1 Capital, and Adiumentum Capital Management, as well as a strategic investment from a large public biotechnology company (Press release, Atara Biotherapeutics, SEP 3, 2024, View Source [SID1234646281]). The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable upon issuance. The offering is expected to close on or about September 5, 2024, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the offering, Greg Ciongoli, founder and managing partner of Adiumentum Capital Management, will join Atara’s Board of Directors.

"Atara’s innovative cell therapies, like tab-cel and its differentiated allogeneic CAR-T portfolio, have the potential to transform the lives of cancer and autoimmune patients," said Greg Ciongoli. "With the prospective U.S. approval for tab-cel and several anticipated CAR-T data readouts all approaching, this is an exciting time to join Atara’s Board and to partner with its strong leadership team."

"We are very pleased to have Greg join our Board, and I look forward to collaborating with him as I transition to Chairman," said Pascal Touchon, President and Chief Executive Officer. "He has over two decades of investing experience and deep industry knowledge, which will complement our Board of Directors well."

The gross proceeds to Atara from the offering are expected to be $36 million, before deducting estimated offering expenses payable by Atara. Atara currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

The securities described above are being offered by Atara pursuant to a shelf registration statement on Form S-3 (No. 333-275256), including a base prospectus, that was previously filed by Atara with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on November 13, 2023. A prospectus supplement containing additional information relating to the offering will be filed with the SEC and will be available on the SEC’s website located at View Source

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On September 3, 2024 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that the inventor of its ovarian cancer CAR-T technology, Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) (Free AACR Whitepaper) 15th Biennial Ovarian Cancer Research Symposium (Press release, Anixa Biosciences, SEP 3, 2024, View Source [SID1234646280]). Dr. Conejo-Garcia will be giving the opening keynote address on Friday, September 20, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the keynote address, Dr. Conejo-Garcia will discuss Anixa’s chimeric antigen receptor-T cell (CAR-T) technology, which is an autologous cell therapy comprised of engineered T cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone (chimeric endocrine) receptor, and the target-binding domain is derived from its natural ligand, this technology is known as CER-T (chimeric endocrine receptor-T cell) therapy, a new type of CAR-T. Anixa holds an exclusive world-wide license to the technology from The Wistar Institute. Dr. Conejo-Garcia will also discuss the ongoing Phase 1 clinical trial of this technology.

"I am pleased to discuss this novel FSHR-mediated CAR-T technology at the Ovarian Cancer Research Symposium and to share ideas and advance the field of ovarian cancer research," stated Dr. Conejo-Garcia. "Anixa and its development partner, Moffitt Cancer Center, have been working together to advance this ovarian cancer therapy and we are excited about the clinical results to date—with the treatment appearing to be safe and well-tolerated, and some patients exhibiting tumor necrosis. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer."

More information about the event may be found at: View Source

On September 3, 2024 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported that members of its management team will participate in upcoming investor conferences in September 2024 (Press release, Abeona Therapeutics, SEP 3, 2024, View Source [SID1234646279]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference: Investor meetings on Thursday, September 5, 2024.
H.C. Wainwright Annual Global Investment Conference: Company presentation on Tuesday, September 10, 2024 at 1:30 p.m. ET and investor meetings.
Cantor Global Healthcare Conference: Fireside chat on Thursday, September 19, 2024 at 9:45 a.m. ET and investor meetings.

A live webcast of the presentation and fireside chat can be accessed on the Investors section of the Abeona website under "Events" at View Source, where a replay of the events will also be available for a limited time.